MedTrace Logo

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

NCT05662215 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-10-17

No results posted yet for this study

Summary

1. Learn about the safety and tolerability of CK-3828136 after a single dose and multiple doses in healthy subjects.
2. Find out how much CK-3828136 is in the blood after a single dose and multiple doses.
3. Determine the effect different doses of CK-3828136 on the pumping function of the heart.

Conditions

  • Healthy Participants

Interventions

DRUG

CK-3828136

CK-3828136

DRUG

Placebo for CK-3828136

Placebo for CK-3828136

Sponsors & Collaborators

  • Cytokinetics

    lead INDUSTRY

Principal Investigators

  • Cytokinetics, MD · Cytokinetics

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-06
Primary Completion
2023-08-08
Completion
2023-08-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05662215 on ClinicalTrials.gov